Your browser doesn't support javascript.
loading
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.
Maeda, Akimitsu; Ando, Hitoshi; Ura, Takashi; Muro, Kei; Aoki, Masahiro; Saito, Ken; Kondo, Eisaku; Takahashi, Shinji; Ito, Yuko; Mizuno, Yasunari; Fujimura, Akio.
Afiliación
  • Maeda A; Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan m.akimitsu@aichi-cc.jp.
  • Ando H; Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan.
  • Ura T; Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan.
  • Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Aoki M; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Saito K; Division of Molecular Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Kondo E; Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Takahashi S; Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Ito Y; Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Mizuno Y; Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Fujimura A; Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.
Anticancer Res ; 37(9): 5235-5239, 2017 09.
Article en En | MEDLINE | ID: mdl-28870959
BACKGROUND/AIM: We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. PATIENTS AND METHODS: We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline. RESULTS: NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline. CONCLUSION: Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.
Asunto(s)
Palabras clave
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Cisplatino / Lesión Renal Aguda / Neoplasias Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Anticancer Res Año: 2017 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Cisplatino / Lesión Renal Aguda / Neoplasias Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Anticancer Res Año: 2017 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia